Survival Disparities in US Black Compared to White Women with Hormone Receptor Positive-HER2 Negative Breast Cancer

Leann A. Lovejoy, Craig D. Shriver, Svasti Haricharan, Rachel E. Ellsworth*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

8 Scopus citations

Abstract

Black women in the US have significantly higher breast cancer mortality than White women. Within biomarker-defined tumor subtypes, disparate outcomes seem to be limited to women with hormone receptor positive and HER2 negative (HR+/HER2−) breast cancer, a subtype usually associated with favorable prognosis. In this review, we present data from an array of studies that demonstrate significantly higher mortality in Black compared to White women with HR+/HER2-breast cancer and contrast these data to studies from integrated healthcare systems that failed to find survival differences. Then, we describe factors, both biological and non-biological, that may contribute to disparate survival in Black women.

Original languageEnglish
Article number2903
JournalInternational Journal of Environmental Research and Public Health
Volume20
Issue number4
DOIs
StatePublished - Feb 2023
Externally publishedYes

Keywords

  • Black
  • biological
  • breast cancer
  • disparity
  • hormone receptor positive/HER2 negative
  • treatment

Fingerprint

Dive into the research topics of 'Survival Disparities in US Black Compared to White Women with Hormone Receptor Positive-HER2 Negative Breast Cancer'. Together they form a unique fingerprint.

Cite this